Commercial Channels

Latest News

Almirall, Novo Nordisk Reach Licensing Agreement Surrounding IL-21 Blocking Monoclonal Antibodies
Almirall, Novo Nordisk Reach Licensing Agreement Surrounding IL-21 Blocking Monoclonal Antibodies

February 20th 2024

As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications.

ValGenesis, RxCloud Collaborate on Tackling Compliance and Quality Assurance Challenges
ValGenesis, RxCloud Collaborate on Tackling Compliance and Quality Assurance Challenges

February 19th 2024

Strategizing High-Wire, Multi-Indication Launches
Strategizing High-Wire, Multi-Indication Launches

February 14th 2024

Regeneron Acquires 2seventy bio’s Novel Immune Cell Therapy Pipeline
Regeneron Acquires 2seventy bio’s Novel Immune Cell Therapy Pipeline

February 1st 2024

Image credit: piter2121 | stock.adobe.com
Eli Lilly Announces New Telehealth, Home Delivery Option for Popular Weight Loss Drug

January 5th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.